Easterly Investment Partners LLC Buys 96,912 Shares of Progyny, Inc. $PGNY

Easterly Investment Partners LLC raised its stake in Progyny, Inc. (NASDAQ:PGNY) by 197.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 146,013 shares of the company’s stock after acquiring an additional 96,912 shares during the period. Easterly Investment Partners LLC’s holdings in Progyny were worth $3,750,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Norges Bank bought a new stake in Progyny in the 4th quarter valued at $10,167,000. Eurizon Capital SGR S.p.A. bought a new stake in Progyny in the 4th quarter valued at $108,000. Jupiter Asset Management Ltd. increased its holdings in Progyny by 24.3% in the 4th quarter. Jupiter Asset Management Ltd. now owns 620,216 shares of the company’s stock valued at $15,927,000 after acquiring an additional 121,233 shares during the last quarter. Geode Capital Management LLC increased its holdings in Progyny by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after acquiring an additional 20,533 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC bought a new stake in Progyny in the 4th quarter valued at $410,000. 94.93% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Progyny

In related news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Melissa B. Cummings sold 9,578 shares of Progyny stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total transaction of $239,450.00. Following the transaction, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. This represents a 11.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 28,609 shares of company stock valued at $679,446. Corporate insiders own 9.90% of the company’s stock.

Progyny Price Performance

Progyny stock opened at $25.56 on Monday. The company’s 50-day moving average price is $19.83 and its 200-day moving average price is $22.24. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $28.75. The company has a market cap of $2.00 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 1.36 and a beta of 1.03.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. During the same period in the previous year, the firm posted $0.17 EPS. The business’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, sell-side analysts expect that Progyny, Inc. will post 1.12 earnings per share for the current fiscal year.

Progyny declared that its board has approved a share repurchase program on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to purchase up to 10.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts have issued reports on PGNY shares. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. KeyCorp reduced their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Citizens Jmp boosted their target price on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. Barclays boosted their target price on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny has a consensus rating of “Moderate Buy” and an average target price of $29.55.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.